News | January 28, 2025
RPG Life Sciences posts Q3 FY25 PAT higher at Rs. 34.93 Cr
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
PAT after MI is Rs. 41 crore which is 162% increase
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
EBITDA margins expand to 31.3%
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Subscribe To Our Newsletter & Stay Updated
